An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)
CytoDyn, Inc.
CytoDyn, Inc.
Novartis
Novartis
Aveni Foundation
AVM Biotechnology Inc
CytoDyn, Inc.
Seagen Inc.
Merus B.V.